Table 3.

Response and clinical benefit according to ERCC1, XPD, and CDA genotype

GenotypePRSD+PDPPR+SDPDP
No. patients (%)No. patients (%)No. patients (%)No. patients (%)
ERCC1 C118T
    C/C2 (25.0)6 (75.0)4 (50.0)4 (50.0)
    C/T16 (41.0)23 (59.0)0.6531 (79.5)8 (20.5)0.03
    T/T6 (33.3)12 (66.7)17 (94.4)1 (5.6)
XPD Lys751Gln
    Lys/Lys9 (45.0)11 (55.0)17 (85.0)3 (15.0)
    Lys/Gln13 (41.9)18 (58.1)0.3026 (83.9)5 (16.1)0.25
    Gln/Gln2 (14.3)12 (85.7)9 (64.3)5 (35.7)
XPD Asp312Asn
    Asp/Asp9 (42.9)12 (57.1)18 (85.7)3 (14.3)
    Asp/Asn11 (34.4)21 (65.6)0.8226 (81.2)6 (18.8)0.44
    Asn/Asn4 (33.3)8 (66.7)8 (66.7)4 (33.3)
CDA Lys27Gln
    Lys/Lys14 (51.9)13 (48.1)25 (92.6)2 (7.4)
    Lys/Gln9 (31.0)20 (69.0)0.0622 (75.9)7 (24.1)0.04
    Gln/Gln1 (11.1)8 (88.9)5 (55.6)4 (44.4)
  • Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease.